DESTROYING CANCER AT THE SPEED OF LIGHT Trademark
Trademark Overview
On Wednesday, June 23, 2021, a trademark application was filed for DESTROYING CANCER AT THE SPEED OF LIGHT with the United States Patent and Trademark Office. The USPTO has given the DESTROYING CANCER AT THE SPEED OF LIGHT trademark a serial number of 90789850. The federal status of this trademark filing is REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED as of Tuesday, January 9, 2024. This trademark is owned by Theralase Technologies Inc.. The DESTROYING CANCER AT THE SPEED OF LIGHT trademark is filed in the Pharmaceutical Products category with the following description:
Photosensitizing agents for photodynamic therapy, namely, light-activated compounds in the nature of therapeutic agents for killing tumor cells and other hyperproliferating cells; photosensitizing agents for photo-activated disinfection, namely, light-activated therapeutic agents for killing pathogens; light-activated disinfectant compositions in the nature of disinfectants for killing pathogens; light-activated photosensitizing compositions in the nature of therapeutic agents for killing tumor cells
General Information
Serial Number | 90789850 |
Word Mark | DESTROYING CANCER AT THE SPEED OF LIGHT |
Filing Date | Wednesday, June 23, 2021 |
Status | 654 - REPORT COMPLETED SUSPENSION CHECK - CASE STILL SUSPENDED |
Status Date | Tuesday, January 9, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
Goods and Services | Photosensitizing agents for photodynamic therapy, namely, light-activated compounds in the nature of therapeutic agents for killing tumor cells and other hyperproliferating cells; photosensitizing agents for photo-activated disinfection, namely, light-activated therapeutic agents for killing pathogens; light-activated disinfectant compositions in the nature of disinfectants for killing pathogens; light-activated photosensitizing compositions in the nature of therapeutic agents for killing tumor cells |
Classification Information
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Wednesday, September 8, 2021 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
Party Name | Theralase Technologies Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Toronto M4B3G4 CA |
Trademark Events
Event Date | Event Description |
Tuesday, January 9, 2024 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
Wednesday, July 12, 2023 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
Wednesday, July 12, 2023 | LETTER OF SUSPENSION E-MAILED |
Wednesday, July 12, 2023 | SUSPENSION LETTER WRITTEN |
Tuesday, July 11, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Tuesday, July 11, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Tuesday, July 11, 2023 | ASSIGNED TO LIE |
Friday, March 10, 2023 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
Wednesday, September 14, 2022 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
Wednesday, September 14, 2022 | INQUIRY TO SUSPENSION E-MAILED |
Wednesday, September 14, 2022 | SUSPENSION INQUIRY WRITTEN |
Thursday, March 17, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
Thursday, March 17, 2022 | LETTER OF SUSPENSION E-MAILED |
Thursday, March 17, 2022 | SUSPENSION LETTER WRITTEN |
Tuesday, March 15, 2022 | ASSIGNED TO EXAMINER |
Wednesday, September 8, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Saturday, June 26, 2021 | NEW APPLICATION ENTERED |